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Background
Among grape skin polyphenols, trans-resveratrol (RES)
has been reported to slow the development of cardiac
fibrosis and to affect myofibroblast (MFB) differentia-
tion. Because MFBs induce slow conduction and ectopic
activity following heterocellular gap junctional coupling
to cardiomyocytes, we investigated whether RES and its
main metabolites affect arrhythmogenic cardiomyocyte-
MFB interactions.
Methods
Experiments were performed with patterned growth
strands of neonatal rat ventricular cardiomyocytes
coated with cardiac MFBs. Impulse propagation charac-
teristics were measured optically using voltage-sensitive
dyes. Long-term video recordings served to characterize
drug-related effects on ectopic activity. Data are given as
means ± S.D. (n = 4–20).
Results
Exposure of pure cardiomyocyte strands to RES at con-
centrations up to 10 µmol/L had no significant effects
on impulse conduction velocity (θ) and maximal action
potential upstroke velocities (dV/dtmax). By contrast, in
MFB-coated strands exhibiting slow conduction, RES
enhanced θ with an EC50 of ~10 nmol/L from 226 ± 38
to 344 ± 24 mm/s and dV/dtmax from 48 ± 7 to 69 ±
2%APA/ms, i.e., to values of pure cardiomyocyte strands
(347 ± 33 mm/s; 75 ± 4%APA/ms). Moreover, RES led
to a reduction of ectopic activity over the course of sev-
eral hours in heterocellular preparations. RES is metabo-
lized quickly in the body; therefore, we tested the main
known metabolites for functional effects and found
them similarly effective in normalizing conduction with
EC50s of ~10 nmol/L (3-OH-RES), ~20 nmol/L (RES-3-
O-b-glucuronide) and ~10 nmol/L (RES-sulfate), respec-
tively. At these concentrations, neither RES nor its
metabolites had any effects on MFB morphology and
a-smooth muscle actin expression. This suggests that
the antiarrhythmic effects observed were based on
mechanisms different from a change in MFB phenotype.
Conclusions
The results demonstrate that RES counteracts MFB-
dependent arrhythmogenic slow conduction and ectopic
activity at physiologically relevant concentrations.
Because RES is rapidly metabolized following intestinal
absorption, the finding of equal antiarrhythmic effective-
ness of the main RES metabolit e sw a r r a n t st h e i ri n c l u -
sion in future studies of potentially beneficial effects of
these substances on the heart.
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